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Stress-specific p38 MAPK activation is sufficient to drive EGFR
endocytosis but not its nuclear translocation
Alejandra Tomas1,*,‡, Sylwia Jones2,‡, Simon O. Vaughan1, Daniel Hochhauser2 and Clare E. Futter1,§
ABSTRACT
EGF receptor (EGFR) endocytosis is induced by stress in a manner
dependent on the p38 MAPK family. Ligand and stresses such as
X-rays, reportedly promote nuclear trafficking of endocytosed EGFR
for regulation of gene transcription and DNA repair. We fail to detect
EGFR endocytosis or nuclear transport following X-ray treatment of
HeLa or head and neck cancer cells, despite extensive DNA damage
induction. Apparent nuclear staining with EGFR extracellular domain
antibody remained present despite reduced/absent EGFR
expression, and so did not represent nuclear EGFR. UVB and
UVC, but not X-ray or UVA, treatment induced p38 activation and
EGFR endocytosis, although all of these stresses induced DNA
damage, indicating that DNA damage alone is not sufficient to induce
EGFR endocytosis. Increased reactive oxygen species (ROS) levels
following UVB treatment, compared to that seen with X-rays, do not
alone explain differences in p38 activation. UVB, like UVC, induced
EGFR accumulation predominantly in perinuclear endosomes, rather
than in the nucleus. Our morphological techniques identifying major
changes in receptor distribution do not exclude the possibility that
small but biologically relevant amounts of EGFR enter the nucleus.
This study highlights the importance and limitations of morphological
analyses of receptor distribution in understanding signaling outcome.
KEY WORDS: EGF receptor, p38 MAPK, Endocytosis, Nuclear
translocation
INTRODUCTION
The ligand-stimulated endocytosis of EGF receptor (EGFR) and
endosomal sorting complexes required for transport (ESCRT)-
dependent delivery to lysosomes is a well-described pathway that
is known to regulate EGFR signaling (Tomas et al., 2014). EGFR
endocytosis can also be promoted by various stresses that induce
DNA damage, including ultraviolet (UV) light, X-rays and
chemotherapeutic agents like cisplatin. The fates of endocytosed
EGFR induced by stress are less well-characterized, but have been
reported to include import into the nucleus where the receptor can
promote transcription of genes associated with cell proliferation and
also promote DNA repair (Wang and Hung, 2012). The transport of
full-length EGFR to the nucleus remains controversial despite being
widely reported following exposure not only to DNA damage-
inducing agents (Dittmann et al., 2008; Hsu et al., 2009; Liccardi
et al., 2011; Xu et al., 2009) but also to ligand (Liao and Carpenter,
2007; Lin et al., 2001). Although EGFR trafficking in response to
stress is a topic of comparatively recent interest, the trafficking of
ligand-stimulated receptor has been extensively studied over many
years and in the majority of these studies nuclear trafficking was not
reported. One possible reason for this discrepancy is that, according
to some reports, only a small proportion of EGFR traffics to the
nucleus and this can take many hours (Liao and Carpenter, 2007),
whereas most analyses of EGFR endocytosis have focused on
events occurring within the first 1–2 h. However, other studies
report transport of EGFR to the nucleus within minutes of EGF
stimulation (Lin et al., 2001).
Nuclear EGFR is of huge potential interest in the diagnosis and
treatment of cancer. EGFR is overexpressed in ∼50% of human
cancers and is a target for cancer therapies. Many studies have
reported nuclear EGFR in tumors where it is associated with poor
prognosis (Lo et al., 2005; Xia et al., 2009). Nuclear transport of
substantial amounts of EGFR after treatment of cultured cells with
X-rays or the chemotherapeutic drug cisplatin, has been implicated
in the repair of double-stranded DNA breaks through interaction
with DNA-dependent protein kinase (DNA-PK) and PCNA (Hsu
et al., 2009; Liccardi et al., 2011;Wang et al., 2012). This provides a
potential mechanism whereby anti-EGFR therapeutics that inhibit
EGFR trafficking and/or signaling could potentiate the effects of
X-rays and chemotherapeutics aimed at inducing tumor cell death
through DNA damage.
One reason for skepticism concerning the possibility of full-
length EGFR entering the nucleus has been the conundrum of how
the receptor can be extracted from the membrane, enter the nucleus
and accumulate in the nucleoplasm. Evidence for a potential
pathway has accumulated over the last 10 years. Although the initial
step of endocytosis has been investigated for both ligand-stimulated
and stress-induced EGFR, the majority of studies of the post-
endocytic traffic of EGFR to the nucleus have focused on EGF-
stimulated EGFR. Following endocytosis, either by clathrin-coated
pits or caveolae, EGFR is proposed to undergo syntaxin
6-dependent trafficking from early endosomes to the Golgi (Du
et al., 2014), followed by COP1-dependent retrograde trafficking to
the endoplasmic reticulum (ER) (Liao and Carpenter, 2007; Wang
et al., 2010a). This is a well-characterized route taken by a number
of exogenous viruses and toxins following endocytosis (Spooner
et al., 2006). Nuclear transport of EGFR depends on Sec61β (Liao
and Carpenter, 2007), suggesting that the transmembrane receptor
may be removed from the ER membrane via the Sec61 translocon
that removes misfolded proteins from the ER lumen for degradation
by the proteasome. The EGFR may escape this fate by associationReceived 19 February 2017; Accepted 19 June 2017
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with chaperones before importin 1β-dependent nuclear import via
the nuclear pore complex (Lo et al., 2006). A pool of Sec61β has
also been found on the inner nuclear membrane leading to the
suggestion that EGFRmay traffic to the inner nuclear membrane via
the nuclear pore and then undergo Sec61-dependent removal from
the membrane into the nucleoplasm (Wang et al., 2010b).
We previously found that UVC and the chemotherapeutic
drug cisplatin induce internalization of EGFR in HeLa cells, and
that this internalization can be prevented by an inhibitor of p38
MAPK α and β (also known as MAPK14 and MAPK11,
respectively). However, the primary destination of the internalized
receptor was perinuclear multivesicular endosomes/bodies (MVBs),
rather than the nucleus (Tomas et al., 2015). Nevertheless, we showed
that signaling from EGFR in perinuclear MVBs delayed onset of
UVC and cisplatin-induced apoptosis. In the current study, we aimed
to investigate the relationship between DNA damage, endocytosis
and nuclear transport of EGFR.We initially focused onDNA damage
induced by X-rays as this has been reported to induce rapid nuclear
translocation of a large proportion of cellular EGFR and to be
associated with EGFR-dependent promotion of DNA repair.
RESULTS
X-ray treatment does not induce significant nuclear
translocation of EGFR in HeLa or SCC47 head and neck
cancer cells
Immunofluorescence (IF) of HeLa cells using both the extracellular
and cytoplasmic domain anti-EGFR antibodies showed that the
majority of EGFR staining was localized to the plasma membrane in
both untreated controls and cells exposed to 4 Gy X-rays, a typical
patient dose (Fig. 1A). A few anti-EGFR-positive puncta overlaid
DAPI-labeled nuclei in control cells, but this was not perceptibly
increased followingX-ray treatment. TodeterminewhetherHeLacells
are unusual in their response to X-rays, SCC47 cells, which are a head
and neck cancer cell line where the EGFR is a relevant therapeutic
target, were also investigated (Fig. 1B). EGF stimulation of these cells
led to punctate anti-EGFR staining throughout the cytoplasm after
30 min of EGF treatment, as previously demonstrated in many cell
types. In contrast, 30 min after X-ray treatment the majority of EGFR
remained localized to the plasma membrane, as in control cells.
A few anti-EGFR-positive puncta did overlay the nucleus in
both control and X-ray-treated HeLa cells. Although confocal
microscopy allows optical sections to be analyzed, it remains
possible for punctate staining that lies immediately below or above
the nucleus to appear nuclear, especially as the nucleus is not a perfect
sphere andendosomal punctacan lie innuclear ‘dimples’. Furthermore,
the nucleus is known to be difficult to permeabilize effectively, raising
the possibility that the scarcity of nuclear staining following X-ray
treatment could be due to a problem of antibody accessibility. To
overcome these potential issues, we prepared cryosections of HeLa cell
pellets using a cryo-ultramicrotome that allows semi-thin (0.5 µm)
sections to be cut, which are too thin to contain the full thickness of the
nucleus, meaning that signal that overlays DAPI stainingmust be in the
nucleus. Furthermore, immunolabeling of the surface of thawed
cryosections with anti-EGFR antibody overcomes the need for the
nucleus to be permeabilized. An anti-EGFR antibody against the
extracellular domain of the receptor revealed some nuclear staining,
which was increased following X-ray treatment but no nuclear staining
in either control or X-ray-treated cells was present with a cytoplasmic
domain anti-EGFR antibody (Fig. 2A).
To determine whether the nuclear staining obtained with the
extracellular domain antibody represented bona fide EGFR staining,
HeLa cells were depleted of EGFR using siRNA against the EGFR
untranslated region (UTR). Western blotting showed that this
treatment removed ∼80% of the cellular EGFR content, and
immunofluorescent labeling of semi-thin cryosections revealed a
clear loss of plasma membrane staining in X-ray-treated cells
(Fig. 2B). However, the nuclear staining was undiminished by
siRNA treatment, raising the possibility that the nuclear staining
was not derived from the EGFR. siRNA-mediated depletion is not
100% effective and is less effective against long-lived proteins and
so the possibility remained that either the nuclear pool for EGFR
was a long-lived one that was resistant to siRNA or that the pool of
EGFR that remains after RNAi treatment is sufficient to give a
nuclear signal. We therefore turned to NIH3T3 cells, which lack
EGFR. In these cells, although no plasma membrane or cytoplasmic
staining was obtained with either extracellular or cytoplasmic
domain antibodies, the extracellular domain antibody gave a strong
nuclear signal following staining of ultrathin cryosections of X-ray-
treated cells (Fig. 2C). Taken together, these results suggest that the
majority of EGFR does not enter the nucleus in HeLa and SCC47
cells after X-ray treatment but some anti-EGFR antibodies can
recognize non-EGFR epitopes in the nucleus that become more
accessible after X-ray treatment.
As antibody staining is subject to the limitations and variations
that arise from the characteristics of the particular antibody used (as
exemplified by the experiments described above), we attempted to
measure X-ray-induced nuclear trafficking of EGFR using
expressed EGFR–GFP, which can be visualized without the use
of antibodies. This chimera has been shown to undergo ligand-
stimulated endocytosis and signaling indistinguishably from the
wild-type protein (Carter and Sorkin, 1998). As shown in Fig. 3A, at
very high levels of expression transiently transfected EGFR–GFP
can be visualized in the biosynthetic pathway as well as at the
plasma membrane but, even at these very high expression levels,
EGFR–GFP could not be detected in the nucleus in untreated or
X-ray-treated cells. At lower levels of expression, EGFR–GFP
remained predominantly plasma membrane-located following
X-ray treatment (Fig. 3B).
Stimuli that induce DNA damage differ in their ability to
induce EGFR internalization in HeLa cells
The results above indicate that not only did X-rays fail to induce
significant translocation of EGFR to the nucleus but that the
majority of the EGFR remained on the cell surface. This was
surprising as endocytosis and nuclear transport of EGFR has been
linked to DNA repair following X-ray (and other) stimuli. In
addition, although we did not detect nuclear transport, we had
previously been able to detect substantial endocytosis following
other stress inducers that cause DNA damage (UVC and cisplatin)
(Tomas et al., 2015). To determine whether DNA damage is
sufficient to induce EGFR internalization in HeLa cells, the effects
of X-rays, cisplatin, UVA and UVC were compared. Staining of
phosphorylated histone 2AX (H2AX, also known as H2AFX; the
phosphorylated form is denoted γH2AX), which is recruited to sites
of DNA damage, demonstrated that all of these stress-inducers
caused DNA damage under the conditions used (Fig. 4A).
However, immunofluorescent anti-EGFR staining showed that
although UVC and cisplatin induced perinuclear accumulation of
EGFR, in UVA- and X-ray-treated HeLa cells anti-EGFR staining
remained predominantly on the plasma membrane (Fig. 4B).
Consistently, quantification of EGFR surface levels through ‘in-
cell western’ experiments demonstrated an ∼50% reduction in
surface EGFR following UVC but not UVA or X-ray treatment
(Fig. S1). Interestingly, although X-ray treatment did not induce
2482
RESEARCH ARTICLE Journal of Cell Science (2017) 130, 2481-2490 doi:10.1242/jcs.202358
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
redistribution of EGFR from the plasma membrane to endosomes
in SCC47 cells, UVB treatment did induce perinuclear EGFR
accumulation in these cells while both treatments induced
comparable levels of DNA damage (Fig. 5). Redistribution of
EGFR from the cell surface to intracellular puncta following
cisplatin, UVB and UVC treatment is consistent with the induction
of EGFR endocytosis under these conditions. In a previous study,
we confirmed the identity of the intracellular compartments in
which EGFR accumulated following UVC and cisplatin treatment
as multivesicular endosomes/bodies (MVBs) in which anti-EGFR
extracellular domain antibody coupled to colloidal gold fed from the
cell surface was internalized following these treatments. Here, we
also show that cycloheximide treatment to block de novo EGFR
synthesis does not prevent intracellular EGFR accumulation,
indicating that this pool of EGFR is derived from endocytosis,
rather than from the biosynthetic pathway (Fig. S2). Finally, to
directly demonstrate EGFR endocytosis, we followed the trafficking
of EGFR–GFPwhen expressed in HeLa cells in real-time after UVB
and X-ray treatment. EGFR–GFP in untreated (Fig. 6, Movie 1) and
X-ray treated (Fig. 6, Movie 2) cells remained largely on the plasma
membrane whereas UVB treatment (Fig. 6, Movie 3) induced rapid
endocytosis of EGFR into large intracellular puncta.
Thus, in both HeLa and SCC47 cells, doses of UVA andX-rays that
induce DNA damage do not induce detectable EGFR internalization
whereas UVC, cisplatin and UVB do. Therefore DNA damage per se
is not sufficient to induce major EGFR internalization.
EGFR internalization following treatment with DNA damage-
inducing agents correlates with sustained p38 activation in
HeLa and SCC47 cells
It was previously shown that UVC or cisplatin treatment of
HeLa cells induces substantial activation of p38 proteins, which
Fig. 1. Immunofluorescence of permeabilized
HeLa and SCC47 cells does not reveal increased
nuclear EGFR following X-ray treatment.
(A) HeLa cells were serum starved, treated with a
single dose of X-rays (4 Gy) and then incubated for
30 min before fixation, permeabilization and
staining with anti-EGFR extracellular domain
(green) and cytoplasmic domain (red) antibodies,
and DAPI (blue). Although a small amount of EGFR
staining overlaps with DAPI-stained nuclei this is
present in both control and X-ray-treated cells.
(B) SCC47 cells were serum starved and left
untreated, incubated with EGF for 30 min or were
X-ray treated (4 Gy) followed by a 30 min incubation
before fixation, permeabilization and staining with
anti-EGFR cytoplasmic domain antibody (green)
and Hoechst 33342 (blue). EGFR is distributed in
puncta throughout the cells after EGF stimulation
but remains predominantly associated with the
plasma membrane following X-ray treatment. Scale
bars: 10 μm.
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is required for EGFR endocytosis (Grandal et al., 2012;
Vergarajauregui et al., 2006; Zwang and Yarden, 2006). To
determine whether treatments that fail to induce detectable EGFR
endocytosis also fail to induce p38 activation, the ability of different
stimuli to activate p38 proteins was compared. In HeLa cells doses
of UVA (Fig. 7A) that induce DNA damage failed to induce
detectable p38 activation, as measured by western blotting with an
antibody that detects phosphorylated active p38, in contrast to the
clear signal obtained in UVC-treated cells. Similarly, in SCC47
cells UVB treatment but not X-rays induced detectable p38
phosphorylation (Fig. 7B). P38 activation following UVB, but not
X-ray treatment was confirmed by the demonstration that UVB
treatment induced phosphorylation of EGFR T669, and HSP27 S82
(also known asHSPB1), both known p38 phosphorylation sites.
Does p38 activation and EGFR internalization following
stress require ROS?
p38 can be activated by reactive oxygen species (ROS). X-rays and
UV would be expected to induce ROS production, raising the
question of why X-rays fail to induce p38 activation. We therefore
used the cell permeant reagent 2′,7′-dichlorofluorescin diacetate
(DCFDA), a fluorogenic dye that measures hydroxyl, peroxyl and
Fig. 2. Apparent increase in nuclear
staining of EGFR on sections of X-ray-
treated cells. (A) HeLa cells were serum
starved, and treated with or without a single
dose of X-rays (4 Gy) followed by a 30 min
incubation. Cells were then fixed, cryo-
preserved and embedded, and semi-thin
cryosections were labeled with anti-EGFR
extracellular domain or cytoplasmic domain
antibodies (green) and DAPI (blue). Clear
nuclear staining is evident with the
extracellular domain antibody that is
increased following X-ray treatment and
absent after labeling with anti-cytoplasmic
domain or no primary antibody. (B) HeLa
cells treated with control or EGFR-targeting
siRNAwerewestern blotted with anti-EGFR
antibody to assess efficiency of knockdown
or were treated with X-rays (4 Gy) and
stained with anti-extracellular domain
antibody as in A. Although plasma
membrane staining was greatly reduced
following EGFR depletion, nuclear staining
with anti-extracellular domain antibody was
unaffected. (C) NIH 3T3 cells lacking EGFR
were treated with X-rays and stained as in
A. Nuclear but not plasma membrane
staining was clearly present on sections
stained with extracellular but not
cytoplasmic domain antibody. Scale bars:
10 μm.
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other ROS activity within the cell, to determine whether X-rays and
UVB differ in the extent or persistence of the cellular ROS that they
induce. As shown in Fig. 8A, although ROS were detectable for at
least 6 h after X-ray treatment, UVB induced at least a 5-fold greater
level of detectable ROS production. Treatment with the oxygen
scavenger N-acetyl-L-cysteine (NAC), reduced UVB-induced
cellular ROS levels, such that they were similar to that induced by
a high dose of X-rays (8 Gy).We had already shown that this dose of
X-rays failed to induce detectable EGFR endocytosis (Fig. 5).
However, treatment with NAC did not prevent UVB-induced EGFR
endocytosis (Fig. 8B). Furthermore, NAC treatment did not prevent
UVB-induced p38 activation, as shown by western blotting with
antibodies against phospho-p38 and the phosphorylated p38
substrate Hps27 (Fig. 8C). These results indicate that the ability
of UVB but not X-rays to induce p38 activation and consequent
EGF endocytosis cannot be explained solely by elevated levels of
UVB-induced ROS production.
DISCUSSION
Many studies have reported nuclear transport of EGFR in cultured
tumor cells exposed to ligand (Lin et al., 2001), X-rays (Dittmann
et al., 2005, 2008; Liccardi et al., 2011), UVC (Xu et al., 2009) or
cisplatin (Liccardi et al., 2011). Although many of these studies
have demonstrated increased levels of full-length EGFR in nuclear
fractions following treatment with different stimuli, this approach
relies on the purity of these nuclear fractions. Therefore, most
studies have also shown increased nuclear staining following
immunofluorescent or immunohistochemical analysis. The latter is
sometimes the only available method, for example when analyzing
the distribution of EGFR in tumor specimens, where subcellular
fractionation may not be possible. Many factors could explain our
inability to clearly detect nuclear EGFR following X-ray treatment.
A lack of nuclear staining by immunofluorescence could be due to a
failure to effectively permeabilize the nucleus or nuclear ‘soluble’
EGFR could have an altered conformation rendering it refractive to
staining with certain antibodies. Interaction partners specific to the
nuclear pool of EGFR could mask epitopes, or proteolytic cleavage
of EGFR before or after nuclear import may result in loss of
epitopes. Finally, small amounts of EGFR in the nucleus that are
below the detection limits of our immunofluorescence assays may
nevertheless have important nuclear functions. Our study raises,
however, an important consideration in the detection of nuclear
EGFR, in that some EGFR antibodies detect epitopes in the nucleus
that are present after siRNA-mediated EGFR depletion, and in
cells that do not express EGFR. In our hands, these epitopes are
more accessible when labeling cell sections, rather than whole
Fig. 3. No evidence of nuclear transport of EGFR–GFP. HeLa cells were transiently transfected with EGFR–GFP, serum starved, treated with a single dose of
X-rays (4 Gy) and chased for the indicated times. (A) GFP fluorescence (green) of highly expressing cells. (B) Cells were fixed, permeabilized and stained for
EGFR (red). Highly expressing cells (A) exhibit EGFR–GFP in the biosynthetic pathway as well as the plasma membrane, whereas in cells that expressed less
EGFR–GFP (B) it is largely confined to the plasma membrane. No fluorescence was discernible in the nucleus even after X-ray treatment. Scale bars: 10 μm.
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permeabilized cells, and are increased upon X-ray treatment. This
highlights the importance of performing rigorous controls, as in this
study, when analyzing the presence or absence of nuclear EGFR.
Furthermore, it is noteworthy that nuclear EGFR staining in tumor
tissue sections has been reported with some, but not all, anti-EGFR
antibodies (Xia et al., 2009), and in this situation it may be more
difficult to verify the specificity of staining against EGFR-negative
samples.Thedemonstrationof nuclear transport of a fluorescentEGFR
chimera, thus overcoming the need for antibody staining, would go a
longway towards answering the nuclear import skeptics. However, we
were not successful in demonstrating nuclear import with the EGFR–
GFP chimera approach. In summary, our study does not exclude the
possibility that nuclear transport of EGFRcan occur, but highlights the
danger of relying on immunostaining as sole indication of it.
Although small amounts of EGFR may endocytose following
X-ray treatment in HeLa and SCC47 cells, we found that the
majority of EGFR remains on the cell surface. This is in marked
contrast to the UVC-induced endocytosis of EGFR that we (Tomas
et al., 2015) and others (Grandal et al., 2012; Zwang and Yarden,
2006), have observed. In our previous studies, we used UVC
treatment to investigate the pathway followed by EGFR following
exposure to stress because UVC-induced endocytosis was well
characterized and induces rapid and synchronous endocytosis. We
were also able to demonstrate p38-dependent endocytosis following
treatment with the chemotherapeutic cisplatin. In the present study,
we extended this analysis to include other DNA damage-inducing
stressors, which are either encountered during daily life (UVA and
UVB) or are commonly used cancer therapies (X-rays and cisplatin).
Although all agents induced DNA damage in the majority of cells,
UVC, UVB and cisplatin, but not UVA or X-rays, induced detectable
EGFR endocytosis and accumulation in a perinuclear compartment.
Why do some DNA damage-inducing agents induce EGFR
internalization and some do not? Inhibition of p38 was previously
shown to inhibit UVC and cisplatin-induced EGFR endocytosis
(Vergarajauregui et al., 2006; Winograd-Katz and Levitzki, 2006;
Zwang and Yarden, 2006). Here, we show that the ability of DNA
damage-inducing agents to cause internalization correlates with p38
activation. We cannot eliminate the possibility that transient p38
activation following X-ray or UVA treatment might induce EGFR
endocytosis followed by rapid recycling, as has been previously
demonstrated following stimulation with TNFα (Zwang and Yarden,
2006), but we were unable to detect endocytosed EGFR even after
short times (<10 min) following X-ray treatment.
Why do some DNA damage-inducing stimuli activate p38 and
some do not? Like all MAPK, p38 proteins are activated through
phosphorylation by MAPK kinases (MKK3 and MKK6, also
known as MAP2K3 and MAP2K6, respectively), which in turn are
activated by MAPK kinase kinases (M3Ks) (Son et al., 2013).
ASK1 (also known as MAP3K5) is a M3K playing a major role in
oxidative stress-induced activation of p38 (Shiizaki et al., 2013).
Oxidation of the ASK1-associated protein thioredoxin, releases it
from ASK1 allowing ASK1 oligomerization, autophosphorylation
and activation. Although X-rays are known to induce ROS
production, the extent to which they do so under the conditions
used in this study is much less than UVB, suggesting that a threshold
amount or duration of ROS production is required to activate p38
Fig. 4. UVC and cisplatin, but not UVA or X-rays, induce intracellular EGFR accumulation though all induce DNA damage. (A) HeLa cells were serum
starved, and treated with a single dose of X-rays (4 Gy), UVA (10,000 J/m2) or UVC (100 J/m2) and subsequently incubated for 1 h, or were treated for 6 h
continuously with 200 µM cisplatin. Cells were then fixed, permeabilized and stained for γH2AX (H2-AX, red) and with DAPI (blue). (B) HeLa cells were treated as
above but were stained for EGFR (green) and DAPI (blue). UVC and cisplatin, but not X-rays or UVA induced endocytosis and accumulation of EGFR in a
perinuclear compartment. Scale bars: 10 μm.
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M3Ks. However, although incubation with a ROS scavenger
reduced UVB-induced cellular ROS, it did not prevent UVB-
induced endocytosis or p38 activation, indicating that additional
factors regulate p38 activation following UV treatment. p38 activity
is also regulated through inactivation by a number of phosphatases
(Son et al., 2013). Differential regulation of an inactivating
phosphatase might also contribute to the inability of X-rays and
UVA to induce sustained p38 activation.
How does sustained p38 activation promote EGFR endocytosis?
We previously showed that p38 activity is required not only for
promoting clathrin/AP2-dependent endocytosis from the plasma
membrane but is also required to retain the EGFR in perinuclear
MVBs (Tomas et al., 2015). p38-mediated EGFR T669
phosphorylation may induce a conformational change in the EGFR
cytoplasmic domain, revealing the AP2 interaction sites that are
necessary for p38-dependent endocytosis. We previously showed
that, although the UVC-mediated activation of p38 and retention in
perinuclear MVBs is sustained for many hours, the p38-mediated
phosphorylation of EGFR at T669 is not. It is likely, therefore that
p38-mediated phosphorylation of substrates in addition to the
receptor itself regulate EGFR trafficking. Notably, a recent paper
on opioid receptor recycling showed that the Rab5 effectors, EEA1
and rabenosyn 5, are targets of p38 and phospho-mimetic mutants of
EEA1 can bypass the requirement for p38 in opioid receptor
endocytosis (Mace et al., 2005).
Our demonstration that EGFR endocytosis is not a response to
DNA damage, and does not necessarily result in nuclear
accumulation, suggests that EGFR-stimulated DNA repair may
not depend on endocytosis or nuclear import. Nuclear accumulation
could facilitate interaction with DNA-PK. However, the presence of
a cytoplasmic pool of DNA-PK potentially renders this substrate of
the EGFR kinase accessible without EGFR endocytosis and nuclear
Fig. 5. UVB, but not X-rays, induce substantial intracellular EGFR
accumulation in SCC47 cells.SCC47 cells were serum starved and then were
left untreated or treatedwith a single dose ofUVB or X-rays followed by chase for
the indicated times. Cells were fixed, permeabilized and stained for EGFR
(green) and γH2AX (H2-AX, red) to detect DNA damage. Although both UVB
and X-rays induced DNA damage, only UVB induced endocytosis and
accumulation of EGFR in a perinuclear compartment. Scale bars: 10 μm.
Fig. 6. UVB, but not X-rays, induce endocytosis of EGFR–GFP in HeLa
cells.HeLa cells transiently transfected with EGFR–GFP were left untreated, or
treated with UVB (800 J/m2) or X-rays (8 Gy). Cells were imaged for 30 min with
the first frame taken at 3.5 min and 7.5 min after UVB and X-ray irradiation
respectively, and images were taken every 90 s (see Movies 1–3). In untreated
and X-ray-treated cells there is little change in EGFR–GFP distribution but
EGFR–GFP redistributes from the cell surface to the cell interior after UVB
treatment. Scale bars: 10 µm.
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translocation. Alternatively, very low levels of EGFR endocytosis
and nuclear transport may be sufficient to activate DNA repair. If
not linked with DNA damage/repair, what is the function of the
endocytosis and perinuclear accumulation of a major part of the
cellular complement of EGFR? We previously showed that
internalization of EGFR following cisplatin or UVC treatment
was necessary to induce a low level of sustained EGFR activation
and downstream signaling, which delayed the onset of apoptosis
(Tomas et al., 2015). We did not, however, determine the
downstream signaling pathways that were necessary for delayed
apoptosis. This is an important topic for future study.
We have shown that sustained p38 activation, but not DNA
damage, is sufficient to induce EGFR endocytosis and perinuclear
accumulation of EGFR. Although intracellular EGFR accumulation
delays the onset of apoptosis, it is unable to prevent cell death,
which may in fact be induced by the prolonged p38 activation. Thus,
although perinuclear accumulation of EGFR can bring about short-
term protection, in practice, it may be that perinuclear accumulation
of EGFR in cells in a tumor indicates a state of prolonged p38
activation that precedes cell death. On the other hand, nuclear EGFR
has been implicated in promotion of proliferation and DNA repair
and has been associated with poor prognosis, suggesting that
nuclear EGFR may indicate a different cellular outcome to that
suggested by perinuclear EGFR. This highlights the importance of
understanding how trafficking of EGFR regulates EGFR signaling
and the extent to which the subcellular distribution of EGFR
predicts tumor cell fate. High resolution and carefully controlled
analysis of the subcellular distribution of EGFR in tumors and
analysis of the effect of DNA damage-inducing therapies on that
distribution will shed light on the role of EGFR trafficking in
regulating and predicting therapeutic outcomes.
MATERIALS AND METHODS
Reagents and antibodies
Cisplatin (200 μM) was from Mayne Pharma. Anti-EGFR antibodies used
for immunofluorescence were against the extracellular domain antibody
purified from the mouse 108 hybridoma (ATCC; 1:200), and rabbit anti-
cytoplasmic domain antibodies (4267 Cell Signaling; 1:50). Antibodies
used for western blotting were: anti-EGFR #2239 (1:1000), anti-phospho-
EGFR-Y1068 #2234 (1:500), anti-phospho-EGFR-T669 #3056 (1:500),
anti-p38 #9217 (1:2000), anti-phospho-p38 #4511 (1:1000), anti-Hsp27
#2402 (1:1000), anti-phospho-Hsp27 #9709, and anti-calnexin #2433
(1:1000) all from Cell Signaling. Anti-γH2AX #05-636 (1:100) for
immunofluorescence was from Millipore.
Cell culture, treatments and transfections
HeLa cells were from ATCC, NIH3T3 cells were from CR-UK London
Research Institute and UM-SCC47 head and neck cancer cells were
generously provided by Dr Tim Fenton (UCL Cancer Institute, London,
UK). All cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) in 10% fetal calf serum in 5% CO2. Prior to treatment, cells were
serum-starved overnight (HeLa and 3T3) or for 2 h (SCC47). For X-ray
treatment, cells were exposed to the indicated doses with the A.G.O. HS
321 kV X-ray system at 2 Gy/min and then incubated for the indicated times
in serum-free medium. For UV treatment, cells were exposed to 100 J/m2,
10,000 J/m2, and 800 J/m2 of UVC (254 nm), UVA (364 nm) or UVB
(312 nm), unless otherwise indicated, with CL-1000 UV crosslinkers
(Spectronics corporation) at room temperature immediately after aspirating
the medium, and were then incubated for the indicated times in serum-free
medium. These treatments took from a few seconds to 3 min, depending
upon the crosslinker capacity. For cisplatin treatment, cells were treated
continuously with 200 µm cisplatin in serum-free culture medium.
HeLa cells were transiently transfected with EGFR–GFP (Carter and
Sorkin, 1998) with Lipofectamine 2000 or 3000 reagent (Life
Technologies) following the manufacturer’s guidelines, for 48 h. To
deplete EGFR, HeLa cells were transfected with siRNA targeting the EGFR
UTR (Hs_EGFR_6, QIAGEN) with Lipofectamine RNAiMAX (Life
Technologies) for 72 h.
Immunofluorescence of permeabilized cells
All cells were fixed with 4% paraformaldehyde (PFA). HeLa and NIH3T3
cells were permeabilized with 0.5% Triton X-100 for 10 min, and
SCC47 cells with ice-cold 0.2% Triton X-100 for 3 min. For HeLa and
NIH3T3 cells, blocking and antibody incubations were in PBS with 1%
bovine serum albumin (BSA). SCC47 cells were blocked in 5% BSAwith
10% FBS. After labeling with primary antibodies for 1 h at room
temperature or overnight at 4°C, cells were incubated with Alexa Fluor-
conjugated secondary antibodies for 45–60 min at room temperature.
Coverslips were mounted in Prolong Gold antifade reagent with 4,6-
diamidino-2-phenylindole (DAPI; Life Technologies) or were incubated
with Hoechst 33342 for 30 min at room temperature before mounting in
Prolong Diamond (Life Technologies), and images were acquired with a
Leica TCS SP2 confocal system with a 63× 1.4 NA oil-immersion
objective or a Leica TCS SP3 confocal with a 63× 1.3 NA oil-immersion
objective.
Immunofluorescence of cryosections
Cells were fixed in 4% PFA, quenched with 15 mM glycine, scraped from
the dish and cell pellets were embedded in 12% gelatin. Small blocks
infused with 2.3 M sucrose at 4°C were mounted on pins and frozen in
liquid nitrogen. 0.5 µm sections were cut with a cryo-ultramicrotome at
Fig. 7. UVC and UVB, but not X-rays or UVA, induce sustained p38
activation. (A) HeLa cells were serum starved and treated with a single dose of
UVC (100 J/m2) or UVA (10,000 J/m2), and then chased for 15–30 mins as
indicated. Cell lysates were blotted with antibody against phosphorylated p38
(p-p38). Calnexin was used as a loading control. Note that UVC, but not UVA,
induces p38 activation. (B) SCC47 cells were serum starved and treated with a
single dose of UVB, and then chased for 60 min. Cell lysates were blotted with
the indicated antibodies. Note that UVB, but not X-rays, induced p38 activation
and phosphorylation of the p38 substrates EGFR T669 and Hsp27.
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−80°C, and retrieved in sucrose onto glass slides. Sections were blocked
and labeled with primary and secondary antibodies and visualized as
described above.
Western blotting
HeLa cells were lysed in lysis buffer [20 mM Tris-HCl, 150 mM NaCl,
1 mM EDTA, 1% NP40 (or Triton-X-100), pH 7.4 plus protease inhibitor
Fig. 8. UVB induces more ROS production than X-rays but ROS scavengers do not prevent EGFR endocytosis. (A) SCC47 cells were serum starved and
treated with DCFDA cellular ROS detection solution for 45 min, then treated with 2.5 mM NAC, 1 mM H2O2, X-rays and UVB as indicated, and chased for the
indicated times. Un, untreated. UVB induced greater and more prolonged levels of cellular ROS than X-rays, which were reduced by incubation with the ROS
scavenger NAC. Results are mean±s.e.m. of three observations. (B) SCC47 cells were serum starved, treated with NAC for 60 min, UVB irradiated and chased for
60 min. Cells were then fixed, permeabilized and stained for γH2AX (H2-AX, red) and EGFR. NAC did not prevent endocytosis of EGFR. Scale bars: 10 μm.
(C) SCC47 cells were treatedwith NAC andUVBas in B. Cell lysates werewestern blottedwith the indicated antibodies. NACdid not prevent UVB-induced activation
of p38.
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cocktail (Calbiochem set I) and phosphatase inhibitor cocktail (Calbiochem
set II)]; lysates were fractionated by SDS-PAGE on 10% gels under reducing
conditions and immunoblotted onto nitrocellulose membranes. Bands were
detected by using enhanced chemiluminescence (Pierce), and exposed films
developed on a SRX-101A Film Processor (Konica).
SCC47 cells were lysed with CellLytic M (Sigma-Aldrich) with complete
Mini Protease Inhibitor Cocktail tablets (Sigma-Aldrich) and phosphatase
inhibitors PhosSTOP (Sigma-Aldrich). Lysates were fractionated by
SDS-PAGE on NuPage Novex 4–12% Bis-Tris protein gels (Thermo Fisher)
and immunoblotted onto Immobilon-FL PVDF membrane (Millipore).
Proteins were detected using the Odyssey Imaging System (Li-Cor).
Surface down-regulation ‘in-cell western’ assay
Approximately 65,000 cells were seeded with six replicates per condition in
a 48-well plate. Cells were serum starved overnight and, following the
appropriate treatment, fixed in 4% PFA in PBS for 20 min. Half of the wells
were permeabilized in 0.1% Triton X-100 for 8 min to quantify total EGFR
level while the other half were left untreated to quantify surface EGFR
levels. Cells were processed for in-cell western with the 108 anti-EGFR
antibody followed by IRDye 800CW donkey anti-mouse-IgG secondary
antibody (LI-COR) and DRAQ5 (to quantify cell number). Images were
taken at 700 and 800 nm with a LI-COR Odyssey Infrared Imaging System
and processed in ImageJ. Integrated density for the same area was quantified
for each well and normalized by cell number.
Live-cell imaging of EGFR–GFP
HeLa cells 24 h after transfection with EGFR–GFP were serum-starved
overnight. The medium was then changed to Cell Imaging Medium [Hank’s
balanced salt solution without Phenol Red and sodium bicarbonate (Sigma)
with 10 mM HEPES (Fisher Scientific), pH 7.4, sterile-filtered] and the cells
were irradiated with X-rays or UVB. The images were acquired using a Zeiss
LSM880 inverted confocal microscope with a Plan Apochromat 63×1.4 NA
oil-immersion objective and a photomultiplier tube. The cells were imaged at
37°C for 30 min starting at 7 min post-X-ray and 3.5 min post-UVB irradiation.
Images were acquired every 90 s with a z-stack of 3.2 µm-3.6 µm and an
interval of 0.4 µm. The 3D movies were prepared using Imaris 8.4 software.
Detection of ROS
SCC47 cells in 96-well black clear-bottom plates were serum-starved
overnight in medium without Phenol Red, then washed with 1× DCFDA
buffer [DCFDA cellular ROS detection assay kit (Abcam)] and incubated
with DCFDA for 45 min at 37°C in the dark. The cells were washed in PBS
and placed in starvation medium without Phenol Red and treated with NAC
(2.5 mM,) and H2O2 (1 mM), then irradiated with UVB or X-rays and
incubated for the indicated times. The fluorescence (excitation 485 nm,
emission 535 nm) was read with a Varioskan Lux plate reader (Thermo
Scientific).
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Figure S1 Surface down regulation of EGFR in HeLa cells after treatment with UVC but 
not X-rays or UVA. 	  
HeLa cells were untreated or treated with a single dose of X-rays (4Gy), UVA (10,000J/m2) 
or UVC (100J/m2) and incubated at 37˚C for 60 mins. Surface binding of anti-EGFR 
extracellular domain antibody was then quantitated with and without permeabilisation, 
normalised to total cell number and surface binding expressed as % total. Results are mean 
+/-SD. *P<0.05 (students t test). 
 
 
  
 
Figure S2 Cycloheximide treatment does not affect intracellular accumulation of 
EGFR.  
HeLa cells were pretreated with cycloheximide (CHX) for 2 hours (to prevent protein 
synthesis) and then treated with a single dose of UVC (100J/m2) and staining with anti-
EGFR cytoplasmic domain antibody (green) and Hoechst (blue). UVC treatment induces 
perinuclear accumulation of EGFR in the presence or absence of cycloheximide. Bar: 10µm. 
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Movies	  
Movie	  1	  EGFR-­‐GFP	  remains	  on	  the	  plasma	  membrane	  in	  untreated	  HeLa	  cells	  
HeLa	   cells	   transiently	   transfected	  with	   EGFR-­‐GFP	  were	   serum-­‐starved	  overnight,	   then	   the	  
medium	  was	  replaced	  with	  CIM	  and	  the	  cells	  were	  imaged	  for	  30	  mins	  at	  37˚C	  with	  images	  
acquired	  every	  90	  sec.	  	  Bar:10µm.	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Movie	  2	  EGFR-­‐GFP	  remains	  on	  the	  plasma	  membrane	  after	  X-­‐ray	  treatment	  in	  HeLa	  cells	  
HeLa	   cells	   transiently	   transfected	  with	   EGFR-­‐GFP	  were	   serum-­‐starved	  overnight,	   then	   the	  
medium	  was	  replaced	  with	  CIM	  and	  the	  cells	  were	  treated	  with	  X-­‐rays	  (8Gy).	  The	  cells	  were	  
imaged	  as	  in	  Movie	  1,	  with	  first	  frame	  acquired	  at	  7	  min	  after	  irradiation.	  Bar:10µm.	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Movie	  3	  EGFR-­‐GFP	  moves	  from	  the	  plasma	  membrane	  to	  intracellular	  punctae	  after	  UVB	  
treatment	  in	  HeLa	  cells	  
HeLa	   cells	   transiently	   transfected	  with	   EGFR-­‐GFP	  were	   serum-­‐starved	  overnight,	   then	   the	  
medium	  was	   replaced	  with	  CIM	  and	   the	   cells	  were	   treated	  with	  UVB	   (800J/m2).	   The	   cells	  
were	  imaged	  as	  in	  Movie	  1,	  with	  first	  frame	  acquired	  at	  3.5	  min	  after	  irradiation.	  Bar:10µm.	  
